Cargando…

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients

BACKGROUND: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. METHODS: A retrospective study was carried out...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaosong, Zhu, Siji, Fei, Xiaochun, Garfield, David H., Wu, Jiayi, Huang, Ou, Li, Yafen, Zhu, Li, He, Jianrong, Chen, Weiguo, Jin, Xiaolong, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627413/
https://www.ncbi.nlm.nih.gov/pubmed/26514283
http://dx.doi.org/10.1186/s12885-015-1853-1
_version_ 1782398290124341248
author Chen, Xiaosong
Zhu, Siji
Fei, Xiaochun
Garfield, David H.
Wu, Jiayi
Huang, Ou
Li, Yafen
Zhu, Li
He, Jianrong
Chen, Weiguo
Jin, Xiaolong
Shen, Kunwei
author_facet Chen, Xiaosong
Zhu, Siji
Fei, Xiaochun
Garfield, David H.
Wu, Jiayi
Huang, Ou
Li, Yafen
Zhu, Li
He, Jianrong
Chen, Weiguo
Jin, Xiaolong
Shen, Kunwei
author_sort Chen, Xiaosong
collection PubMed
description BACKGROUND: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. METHODS: A retrospective study was carried out on 276 patients with paired CNB and surgically removed samples (SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value change was calculated as SRS minus CNB. RESULTS: Mean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples: 29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 % within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+ tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed in patients with STI ≥ 5 days. CONCLUSION: CNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to consider Ki67 changes following CNB among different breast cancer molecular subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1853-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4627413
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46274132015-10-31 Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients Chen, Xiaosong Zhu, Siji Fei, Xiaochun Garfield, David H. Wu, Jiayi Huang, Ou Li, Yafen Zhu, Li He, Jianrong Chen, Weiguo Jin, Xiaolong Shen, Kunwei BMC Cancer Research Article BACKGROUND: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. METHODS: A retrospective study was carried out on 276 patients with paired CNB and surgically removed samples (SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value change was calculated as SRS minus CNB. RESULTS: Mean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples: 29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 % within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+ tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed in patients with STI ≥ 5 days. CONCLUSION: CNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to consider Ki67 changes following CNB among different breast cancer molecular subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1853-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-30 /pmc/articles/PMC4627413/ /pubmed/26514283 http://dx.doi.org/10.1186/s12885-015-1853-1 Text en © Chen et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chen, Xiaosong
Zhu, Siji
Fei, Xiaochun
Garfield, David H.
Wu, Jiayi
Huang, Ou
Li, Yafen
Zhu, Li
He, Jianrong
Chen, Weiguo
Jin, Xiaolong
Shen, Kunwei
Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
title Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
title_full Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
title_fullStr Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
title_full_unstemmed Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
title_short Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
title_sort surgery time interval and molecular subtype may influence ki67 change after core needle biopsy in breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627413/
https://www.ncbi.nlm.nih.gov/pubmed/26514283
http://dx.doi.org/10.1186/s12885-015-1853-1
work_keys_str_mv AT chenxiaosong surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT zhusiji surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT feixiaochun surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT garfielddavidh surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT wujiayi surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT huangou surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT liyafen surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT zhuli surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT hejianrong surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT chenweiguo surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT jinxiaolong surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients
AT shenkunwei surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients